# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment o...
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $14...
RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from...